The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Is (S)-norketamine an alternative antidepressant for esketamine?
Open accessAbstract
The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)ketamine has been hailed as the most important advance in the treatment of depression for the past 50 years. The rapid and sustained antidepressant effects of (R,S)-ketamine have spurred a great deal of research interest, with growing off-label use for the treatment of depression, although the concerns about the safety of repeated (R,S)-ketamine infusions persist [1]. (R,S)-ketamine (Ki = 0.53 μM for NMDAR) is a racemic mixture containing equal parts of (R)-ketamine (or arketamine) (Ki = 1.4 μM for NMDAR) and (S)-ketamine (or esketamine) (Ki = 0.30 μM for NMDAR) (Fig. 1). Previously, we reported that (R)-ketamine showed greater potency and longer lasting antidepressant effects than esketamine in animal models of depression [2]. Unlike esketamine, (R)-ketamine does not induce psychotomimetic side effects or exhibit abuse potential in rodents [3]. A positron emission tomography study using conscious monkeys demonstrated a marked reduction in dopamine D2/3 receptor binding in the monkey striatum after a single infusion of esketamine (0.5 mg/kg for 40 min), suggesting a marked release of dopamine from presynaptic terminal [4]. Interestingly, it is reported that a single infusion of esketamine (0.5 mg/kg for 40 min) caused psychotomimetic and dissociative symptoms (e.g., strange experiences like a feeling of floating in outer space or depersonalization/derealization) in patients with treatment-resistant depression [5]. Therefore, it is suggested that esketamine-induced dopamine release might be associated with the acute psychotomimetic and dissociative side effects in humans. Collectively, (R)-ketamine could be a safer antidepressant in humans than esketamine [2–4] . The Janssen Pharmaceutical Companies of Johnson & Johnson has been developing esketamine nasal spray as the novel antidepressant. Two phase 2 randomized clinical trials of intranasal esketamine have been reported. Daly et al. [6] reported the efficacy of intranasal esketamine (28, 56, or 84 mg twice weekly) for the rapid reduction of symptoms of depression and suicidality in treatment-resistant patients. Change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score in all three esketamine groups was superior to placebo, with a significant dose–response relationship [6]. Furthermore, Canuso et al. [7] reported the efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide. Esketamine (84 mg twice weekly for 4 weeks) along with antidepressant treatment significantly decreased suicidal symptoms and depression at both 4 and 24 h; however, these effects did not differ from those of placebo after 4 weeks of treatment. In contrast, differences in suicide risk scores, as determined by clinical global judgment, were not statistically significant between the groups at any time point [7]. Dissociative symptoms began shortly after each infusion and attenuated after repeated doses. The abuse potential of intranasal esketamine was not specifically examined within this short trial [6, 7]. It seems that the effects of intranasal esketamine may be less potent than intravenous (R,S)-ketamine. At the American Psychiatric Association annual meeting in May 2018, the company presented mixed findings of two phase 3 trials for intranasal esketamine [8]. Adult treatment-resistant patients who received esketamine had a significantly greater drop in MADRS score from baseline at day 28 compared with placebo group. In contrast, 65 and older patients with treatment-resistant depression who received esketamine plus a newly initiated oral antidepressant had no statistical difference in change in the MADRS score from baseline to day 28 compared with placebo group [8]. The potential for ketamine abuse is one of the most important drawbacks of repeated ketamine infusions for treating mood disorders [9]. Ketamine-induced rewarding effects are associated with the potent inhibition of the NMDAR in the brain. Esketamine is metabolized into (S)-norketamine (Ki = 1.70 μM for NMDAR) by the microsomal cytochrome P450 system (Fig. 1). Preclinical studies have revealed the * Kenji Hashimoto hashimoto@faculty.chiba-u.jp
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Norketamine has also been investigated to a lesser extent [48] but, to date, no clinical trials have assessed its effects in MDD or BD.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [48]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Intravenous administration provides the most predictable dosing with 100% bioavailability, and availability via other routes of administration including intranasal (45%), sublingual (30%), oral (20%), intramuscular (93%) and rectal (30%) is discussed in the literature.31,34,35,46,54”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredIn the citing paper
“In animal studies, R-ketamine has been reported to have a rapid onset of antidepressant effects and a better side-effect profile than esketamine34–41”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [35]
In the citing paper
“In these animal models, S-norketamine has been reported to be equipotent to S-ketamine with regard to antidepressant-like activity, but less potent than R-ketamine.34,35”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [35]
In the citing paper
“S-norketamine, a metabolite of S-ketamine, has been shown in animal models to have useful antidepressant-like properties and fewer adverse effects than esketamine.35,53”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 137
Self-citationHashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Self-citationHashimoto, K. (2016) · Psychological Medicine · doi:10.1017/s0033291716000969 · Cited by 58
Self-citation
Research works printed but not linked: 1
- Psychiatric News (2018) J&J presents mixed findings for esketamine nasal spray at APA Annual Meeting. https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2018.pp5a2 · doi:10.1176/appi.pn.2018.pp5a2
Cited by
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
“…(arketamine) has greater potency and longer lasting antidepressant effects than (S)-ketamine in animal models of depression, and that arketamine has fewer detrimental side effects than both (R,S)-ketamine or (S)-ketamine (Hashimoto, 2019; Hashimoto and Yang, 2019; Zhang and Hashimoto, 2019a).”
BackgroundHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Taken all together, (S)-norketamine and its prodrugs would be safer antidepressants than (S)-ketamine in humans.(10,141,142) Notably, unlike (S)-ketamine, it should be noted that (S)-norketamine is not a schedule compound.”
BackgroundSelf-citationMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Self-citationMolecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Hashimoto, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113935 · Cited by 236
Self-citationMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Metadata
- Authors
- Hashimoto, K., & Yang, C.
- Affiliations
- Chiba University (JP)
- Tongji Hospital (CN)
- Corresponding author
- Hashimoto, Kenji
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2018-07-14
- Volume
- 269
- Issue
- 7
- Pages
- 867-868
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC6739277
- OpenAlex
- W2884332078
- Cited by
- 37
- References
- 9
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 10 · 2019: 6 · 2018: 1
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18dm0107119)
- National Natural Science Foundation of China (81703482)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, antidepressants, ketamine analogues, treatment-resistant depression
- MeSH terms
- Animals, Antidepressive Agents, Depression, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is (S)-norketamine an alternative antidepressant for esketamine? https://app.cochat.ai/papers/10.1007/s00406-018-0922-2
- The paper
- Hashimoto, K., & Yang, C. (2019). Is (S)-norketamine an alternative antidepressant for esketamine? European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-018-0922-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
